Intrajejunal Vs Oral Levodopa-carbidopa Therapy in Parkinson Disease: A Retrospective Cohort Study

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Nov 12

PMID 33181715

Citations 5

Authors

Luminita C Popa

Daniel-Corneliu Leucuta

Nicoleta Tohanean

Stefan-Lucian Popa

Lacramioara Perju-Dumbrava

Affiliations

Soon will be listed here.

Abstract

Levodopa-carbidopa intestinal gel (LCIG) is a method of continuous administration of levodopa - the standard treatment in Parkinson disease (PD, a neurodegenerative disorder characterized by resting tremor, rigidity, gait impairment, and bradykinesia), thought to reduce the short-life and pulsatile problems of oral administration. We aimed to study the effects of Levodopa-Carbidopa therapy in 2 separate groups: one with intrajejunal administration of Levodopa-Carbidopa gel and the second with oral therapy.We performed an observational retrospective Romanian cohort study on 61 patients diagnosed with PD patients, with Hoehn and Jahr 3 and 4 stages, recruited from a single regional tertiary center in Cluj-Napoca, Romania, between 2009 and 2019.The mean adjusted UPDRS III (and similarly for UPDRS II) improved in the LCIG compared to the oral therapy group with 15.6 (95% CI 12.0-19.2, P < .001), and with 18.4 (95% CI 13.8-22.9, P < .001), stratified for the Hoehn and Jahr stages 3 and 4. There was a 41.7% (10) reduction in dyskinesia, and 29.2% reduction in wearing off/on-off at 1 year in the LCIG group compared to 0% (0) dyskinesia reduction, and 2.7% reduction in wearing off/on-off in the oral therapy group.Continuous intrajejunal infusion of LCIG ensures a significant and clinical reduction in motor fluctuations compared to oral therapy in advanced PD, even after adjustment for important confounders.

Citing Articles

A Comprehensive Approach to Parkinson's Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects.

Muleiro Alvarez M, Cano-Herrera G, Osorio Martinez M, Vega Gonzales-Portillo J, Monroy G, Murguiondo Perez R Int J Mol Sci. 2024; 25(13).

PMID: 39000288 PMC: 11241043. DOI: 10.3390/ijms25137183.

Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa.

Imbeah E, Adi-Dako O, Nguessan B, Kukuia K, Dankyi B, Adams I ADMET DMPK. 2023; 11(1):97-115.

PMID: 36778908 PMC: 9909728. DOI: 10.5599/admet.1474.

Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?.

Rota S, Urso D, van Wamelen D, Leta V, Boura I, Odin P Transl Neurodegener. 2022; 11(1):43.

PMID: 36229860 PMC: 9558383. DOI: 10.1186/s40035-022-00317-x.

Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia-Literature Review.

Hutny M, Hofman J, Klimkowicz-Mrowiec A, Gorzkowska A J Clin Med. 2021; 10(19).

PMID: 34640395 PMC: 8509231. DOI: 10.3390/jcm10194377.

Parkinson's Disease in Romania: A Scoping Review.

Rosca E, Tudor R, Cornea A, Simu M Brain Sci. 2021; 11(6).

PMID: 34071802 PMC: 8226866. DOI: 10.3390/brainsci11060709.

References

Cruse B, Morales-Briceno H, Chang F, Mahant N, Ha A, Kim S . 24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease. NPJ Parkinsons Dis. 2018; 4:34. PMC: 6243994. DOI: 10.1038/s41531-018-0070-4. View

Clarke C, Worth P, Grosset D, Stewart D . Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord. 2009; 15(10):728-41. DOI: 10.1016/j.parkreldis.2009.09.005. View

Olanow C, Kieburtz K, Odin P, Espay A, Standaert D, Fernandez H . Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2013; 13(2):141-9. PMC: 4643396. DOI: 10.1016/S1474-4422(13)70293-X. View

Isacson D, Bingefors K, Kristiansen I, Nyholm D . Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand. 2008; 118(6):379-86. DOI: 10.1111/j.1600-0404.2008.01049.x. View

Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias I, Manfredi L . Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis. 2008; 5(3-4):244-6. DOI: 10.1159/000113714. View

Nyholm D, Nilsson Remahl A, Dizdar N, Constantinescu R, Holmberg B, Jansson R . Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005; 64(2):216-23. DOI: 10.1212/01.WNL.0000149637.70961.4C. View

Wang L, Li J, Chen J . Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis. Front Neurol. 2018; 9:620. PMC: 6077236. DOI: 10.3389/fneur.2018.00620. View

Nilsson D, Nyholm D, Aquilonius S . Duodenal levodopa infusion in Parkinson's disease--long-term experience. Acta Neurol Scand. 2002; 104(6):343-8. DOI: 10.1034/j.1600-0404.2001.00153.x. View

Fernandez H, Vanagunas A, Odin P, Espay A, Hauser R, Standaert D . Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord. 2013; 19(3):339-45. PMC: 3661282. DOI: 10.1016/j.parkreldis.2012.11.020. View

10.

Reichmann H . Premotor Diagnosis of Parkinson's Disease. Neurosci Bull. 2017; 33(5):526-534. PMC: 5636732. DOI: 10.1007/s12264-017-0159-5. View

11.

Ramaker C, Marinus J, Stiggelbout A, Van Hilten B . Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord. 2002; 17(5):867-76. DOI: 10.1002/mds.10248. View

12.

Zulli C, Sica M, De Micco R, Del Prete A, Amato M, Tessitore A . Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study. Eur Rev Med Pharmacol Sci. 2016; 20(11):2413-7. View

13.

Jost W . Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opin Drug Saf. 2014; 13(4):447-58. DOI: 10.1517/14740338.2014.896336. View

14.

Catalan M, Antonini A, Calopa M, Bajenaru O, de Fabregues O, Minguez-Castellanos A . Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. eNeurologicalSci. 2017; 8:44-53. PMC: 5730910. DOI: 10.1016/j.ensci.2017.06.004. View

15.

Slevin J, Fernandez H, Zadikoff C, Hall C, Eaton S, Dubow J . Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients. J Parkinsons Dis. 2015; 5(1):165-74. DOI: 10.3233/JPD-140456. View

16.

Pickut B, Van der Linden C, Dethy S, Van De Maele H, de Beyl D . Intestinal levodopa infusion: the Belgian experience. Neurol Sci. 2014; 35(6):861-6. DOI: 10.1007/s10072-013-1612-5. View

17.

Schapira A, Chaudhuri K, Jenner P . Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017; 18(7):435-450. DOI: 10.1038/nrn.2017.62. View

18.

Fernandez H, Standaert D, Hauser R, Lang A, Fung V, Klostermann F . Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord. 2014; 30(4):500-9. PMC: 4674978. DOI: 10.1002/mds.26123. View

19.

Antonini A, Isaias I, Canesi M, Zibetti M, Mancini F, Manfredi L . Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord. 2007; 22(8):1145-9. DOI: 10.1002/mds.21500. View

20.

Merola A, Espay A, Romagnolo A, Bernardini A, Rizzi L, Rosso M . Advanced therapies in Parkinson's disease: Long-term retrospective study. Parkinsonism Relat Disord. 2016; 29:104-8. DOI: 10.1016/j.parkreldis.2016.05.015. View